Early trials showed good weight loss results
Mild deficiency causes fatigue, brain fog, and mood changes
Primary Medications Available ( per ro.co ): Wegovy (semaglutide 2.4 mg) - FDA-approved for chronic weight management Zepbound (tirzepatide) - FDA-approved for chronic weight management, available in both pen and vial formulations Ozempic (semaglutide 2.0 mg) - FDA-approved for type 2 diabetes, may be prescribed off-label for weight loss Clinical Trial Results for Weight Loss : According to FDA-reviewed clinical trials, Wegovy (semaglutide 2.4 mg) produced average weight loss of 15% of body weight over 68 weeks when combined with lifestyle modifications According to published SURMOUNT trial data, Zepbound (tirzepatide 15 mg) produced average weight loss of 20% of body weight over 72 weeks when combined with lifestyle modifications Both results significantly exceeded placebo groups (2.4-3.1% weight loss) Membership Structure ( per ro.co , November 2025): First Month : $45 introductory rate Ongoing Months : $145/month recurring subscription Medication Costs : Separate from membership, varies by selection and insurance coverage What's Included in Membership ( according to ro.co ): Up to 24 provider consultations annually Unlimited secure messaging with healthcare coach Insurance concierge service for medication coverage assistance Metabolic lab testing when ordered by provider (Quest included for most members) Digital weight tracking and dose logging tools Evidence-based educational curriculum Side effect management support Cash-Pay Medication Pricing ( as listed on ro.co, November 2025, subject to verification): Zepbound vials via LillyDirect: $349-$499/month Wegovy pens via NovoCare: $499/month Zepbound pens: Approximately $1,050/month Ozempic: Pricing varies by pharmacy Insurance Coverage Path : Dedicated concierge team handles prior authorization paperwork Process typically takes 2-3 weeks for coverage determination If approved, members pay only insurance plan copay amounts Appeals assistance available if initially denied Member Survey Data ( per ro.co ): 87% of 1,243 surveyed members reported life-changing results 93% agreed Ro was easier to incorporate than previous weight loss attempts 97% reported reduced "food noise" (reduced food preoccupation) Note: Survey participants were compensated for testimonials Eligibility Requirements : Age 18+ (some services 21+) BMI 30 or BMI 27 with weight-related conditions No personal/family history of medullary thyroid carcinoma (MTC) No Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) Not pregnant or breastfeeding Resident of state where Ro operates State Availability : Available in most U.S
Other combinations of entero-pancreatic hormones, including cagrisema (GLP-1/amylin RA) and the triple agonist retatrutide (GLP-1/GIP/glucagon RA), have progressed to phase 3 trials as obesity treatments, and early data suggest that they may lead to even greater weight loss than tirzepatide [28]
It allows for hormonal stabilization so menstrual cycles can restabilize at your new weight
Youre relying on your digestive system to break it down, extract the amino acids, and deliver them to the right cells at the right time
